MyAlcon Professional Logo

MyAlcon | International

This site is available in English. Select below for other countries.

Select Another Country

Clareon® Vivity® IOL

Simplifying Presbyopia Correction1-8

 

A presbyopia-correcting IOL with wavefront-shaping technology, a clinically proven exceptionally low rate of visual disturbances and unsurpassed clarity1-4,9

Clareon® Vivity® IOL

Simplifying Presbyopia Correction1-8

 

A presbyopia-correcting IOL with wavefront-shaping technology, a clinically proven exceptionally low rate of visual disturbances and unsurpassed clarity1-4,9

 

Blue logo of a weight scale
Blue logo of a weight scale

Clareon® Vivity® and AcrySof IQ Vivity® are Optically and Mechanically Equivalent

An icon of white crosshairs appearing over a blue background.
An icon of white crosshairs appearing over a blue background.

 

IOLs based on Clareon® and AcrySof® have the lowest axial displacement and simulated dioptric power shift versus competitor IOLs10*

An icon of a diamond appearing over a blue background.
An icon of a diamond appearing over a blue background.

 

IOLs based on Clareon® deliver among the lowest levels of haze and roughness, SSNGs and glistenings compared with other IOLs9

An icon of a Vivity IOL with degree measurements on either side to signify axial displacement appearing over a blue background.
An icon of a Vivity IOL with degree measurements on either side to signify axial displacement appearing over a blue background.

 

Along with minimal axial displacement, the Clareon® haptic design, shared with AcrySof® IQ IOLs, contributes to a high rotational stability11

An icon of a clipboard with checkmarks appearing over a blue background.
An icon of a clipboard with checkmarks appearing over a blue background.

 

Additionally, Clareon® and AcrySof® demonstrate Nd:YAG rates that are similar12-14

*Based on comparison of the mean axial displacement of Clareon®, AcrySof®, enVista† MX60, TECNIS† ZCB00 and Vivinex† iSert† XY1 IOLs; n=10 per IOL; p<.005

†Trademarks are the property of their respective owners.

 
 

Hear What Surgeons Are Saying About The Vivity® IOL

 

“This is a really exciting lens… We have been looking for it for a while.”

- Dr. Michael Lawless, MBBS, FRANZCO, FRACS

Surgeon Benefits

 

“The wavefront is actually shaped to be more beneficial to the visual quality and to the visual disturbance profile.” - Dr. Cathleen McCabe, MD

Patient Benefits

 

“The self-reported patient happiness is the best and nicest support I can get to keep doing what I do.” - Dr. Chandra Bala, PhD, MB, BS (Hons), FRANZCO

Opportunities for Surgeons Not Implanting Vivity®

 

“I would definitely recommend this IOL to my peers who are currently not using presbyopia-correcting IOLs.” - Dr. Devesh Varma, MD

Based on surgeons' personal clinical experience.

Clareon® Vivity® Simplifies Presbyopia Correction1-8

 

Clareon® Vivity® provides the same exceptional performance you expect with AcrySof IQ Vivity®, available on Alcon’s most advanced lens platform.

 

  • A visual disturbance profile comparable to a monofocal IOL1,3,4

 

  • Excellent distance, intermediate and functional near vision3,4*

 

  • Presbyopia-correcting performance in an easy-to-use wavefront-shaping IOL1-8

 

  • Exceptional clarity† and stability on Alcon’s most advanced IOL platform to date9

 

*Results from a prospective, randomized, parallel group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof IQ Vivity® Extended Vision IOL and 113 with the AcrySof® IQ IOL with 6 months’ follow-up.

†Among the lowest levels of surface haze, SSNGs, and glistenings of competitive IOLs.

An image of a Clareon Vivity and Clareon Vivity Toric IOL overlapping each other.

Clareon® Vivity® is Designed to Deliver the Same Excellent Distance, Intermediate and Functional Near Vision as AcrySof IQ Vivity®3,4

White icon of a car appearing over a blue background.
White icon of a car appearing over a blue background.

High-quality distance vision comparable to a monofocal

Binocular Mean Uncorrected Distance Visual Acuity (4 m)3,4*†

White icon of a computer desktop appearing over a blue background.
White icon of a computer desktop appearing over a blue background.

Improved intermediate visual acuity compared to a monofocal

Binocular Mean Uncorrected Intermediate Visual Acuity (66 cm)3,4*†

White icon of a cell phone appearing over a blue background.
White icon of a cell phone appearing over a blue background.

Functional near vision for close-up daily activities

Binocular Mean Uncorrected Near Visual Acuity (40 cm)3,4*†

Results from a prospective, randomized, parallel-group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof IQ Vivity® Extended Vision IOL and 113 with the AcrySof® IQ IOL with 6 months’ follow-up.

†Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 ETDRS chart letters in the line were identified correctly.

The Flat Defocus Curve Delivers Confidence in Hitting a Refractive Target3

 

6-month binocular distance corrected defocus curve3*†

Defocus curve graph showing that the defocus range for Clareon Vivity is comparable to that of a monofocal. A number one in a circle draws a line across the distance section of the graph, indicating that the Clareon Vivity IOL is designed to be forgiving and flexible around distance. A number two in a circle draws a line from the distance section of the graph to the near section indicating that Clareon Vivity offers a continuous intermediate range of vision.

*Data obtained from a prospective, randomized controlled trial of 145 subjects bilaterally implanted with the AcrySof IQ Vivity® Extended Vision IOL and 106 with the AcrySof® IQ IOL with 6 months’ follow-up.

†AcrySof IQ Vivity® was tested. AcrySof IQ Vivity® and Clareon® Vivity® are optically equivalent.

‡Monofocal IOL = Model SN60WF.

§Vivity® IOL = Model DFT015.

In All Light Conditions, Vivity® Patients Reported Monofocal-Quality Distance with Excellent Intermediate and Functional Near Vision4

 

Percent of Patients Reporting Good or Very Good Vision Without Spectacles at 6 Months4*†

Bar graph showing the percent of patients reporting good or very good vision at 6 months without spectacles in bright light, where the best outcome would be 100%. 106 patients were implanted with Vivity IOL, and 113 patients were implanted with a monofocal IOL. The graph displays that with the Vivity IOL, 94% of patients at far, 92% of patients at arm’s length, and 57% of patients up-close reported good or very good vision. With the monofocal IOL, 92% of patients at far away, 63% of patients at arm’s length and 25% of patients up close reported good or very good vision. Bar graph showing the percent of patients reporting good or very good vision at 6 months without spectacles in dim light, where the best outcome would be 100%. 106 patients were implanted with Vivity IOL, and 113 patients were implanted with a monofocal IOL. The graph displays that with the Vivity IOL, 88% of patients at far, 83% of patients at arm’s length, and 38% of patients at up-close reported good or very good vision. With the monofocal IOL, 78% of patients at far away, 51% of patients at arm’s length and 8% of patients up close reported good or very good vision.

*Data obtained from a validated IOLSAT questionnaire, patients were asked, "How well did you see without wearing eyeglasses in the past 7 days?”

†Results from a prospective, randomized, parallel group, subject and assessor masked, multisite trial of 107 subjects bilaterally implanted with AcrySof IQ Vivity® Extended Vision IOL and 113 with AcrySof® IQ IOL with 6 months follow-up.

‡Vivity® IOL = AcrySof IQ Vivity®, Model DFT015.

§Monofocal IOL = AcrySof® IQ IOL, Model SN60WF.

Visual Disturbance Profile: Clareon® Vivity® Had an Optical Halo Compared to a Monofocal IOL15

 

Optical bench halo measurements: 4.5 mm pupil size15

Black background with a bright light in the middle representing the optical bench halo measurement for Clareon Monofocal IOL.
Black background with a bright light in the middle representing the optical bench halo measurement for Clareon Monofocal IOL.

 

Clareon®
Monofocal IOL
Black background with a bright light in the middle representing the optical bench halo measurement for Clareon Vivity IOL.
Black background with a bright light in the middle representing the optical bench halo measurement for Clareon Vivity IOL.

 

Clareon® Vivity®
IOL
Black background with a bright light in the middle, with a halo around the light larger than the Clareon Monofocal and Clareon Vivity IOLs, representing the optical bench halo measurement for Clareon PanOptix IOL.
Black background with a bright light in the middle, with a halo around the light larger than the Clareon Monofocal and Clareon Vivity IOLs, representing the optical bench halo measurement for Clareon PanOptix IOL.

 

Clareon®
PanOptix® IOL
Black background with a bright light in the middle, with a halo around the light larger than the Clareon Monofocal and Clareon Vivity IOLs, representing the optical bench halo measurement for TECNIS Synergy IOL.
Black background with a bright light in the middle, with a halo around the light larger than the Clareon Monofocal and Clareon Vivity IOLs, representing the optical bench halo measurement for TECNIS Synergy IOL.

 

TECNIS Synergy*
IOL

These are representative images from a benchtop study.

*Trademarks are the property of their respective owners.

Visual Disturbance Profile: Clareon® Vivity® Had an Optical Halo Compared to a Monofocal IOL5,15

 

Optical bench halo measurements: 4.5 mm pupil size5,15

Black background with a bright light in the middle representing the optical bench halo measurement for Clareon Monofocal IOL.
Black background with a bright light in the middle representing the optical bench halo measurement for Clareon Monofocal IOL.

 

Clareon®
Monofocal IOL
Black background with a bright light in the middle representing the optical bench halo measurement for Clareon Vivity IOL.
Black background with a bright light in the middle representing the optical bench halo measurement for Clareon Vivity IOL.

 

Clareon® Vivity®
IOL
Black background with a bright light in the middle, with a halo around the light larger than the Clareon Monofocal and Clareon Vivity IOLs, representing the optical bench halo measurement for TECNIS Symfony Diffractive IOL.
Black background with a bright light in the middle, with a halo around the light larger than the Clareon Monofocal and Clareon Vivity IOLs, representing the optical bench halo measurement for TECNIS Symfony Diffractive IOL.

 

TECNIS Symfony*
Diffractive EDoF
Black background with a bright light in the middle, with a halo around the light larger than the Clareon Monofocal and Clareon Vivity IOLs, representing the optical bench halo measurement for Zeiss AT LARA Diffractive IOL.
Black background with a bright light in the middle, with a halo around the light larger than the Clareon Monofocal and Clareon Vivity IOLs, representing the optical bench halo measurement for Zeiss AT LARA Diffractive IOL.

 

Zeiss AT LARA* 
Diffractive EDoF

These are representative images from a benchtop study.

*Trademarks are the property of their respective owners.

Clareon® Vivity® IOL Visual Disturbance Profile is Comparable to a Monofocal1,3,4

 

The majority of Vivity® IOL patients were not bothered at all by visual disturbances.1,3,4

Bar graph reporting how bothered patients were by starbursts, halos and glare after implantation with the Vivity IOL and a monofocal IOL. 106 patients were implanted with Vivity IOL, and 110 patients were implanted with a monofocal IOL. The graph displays that with the Vivity IOL, 74% of Vivity patients and 72% of monofocal patients were not bothered at all by starbursts. 83% of Vivity patients and 89% of monofocal patients were not bothered at all by halos. 78% of Vivity patients and 76% of monofocal patients were not bothered at all by glare. 14% of Vivity patients and 15% of monofocal patients were bothered a little by starbursts. 12% of Vivity patients and 6% of monofocal patients were bothered a little by halos. 11% of Vivity patients and 10% of monofocal patients were bothered a little by glare. 9% of Vivity patients and 11% of monofocal patients were bothered somewhat by starbursts. 3% of Vivity patients and 5% of monofocal patients were bothered somewhat by halos. 7% of Vivity patients and 12% of monofocal patients were bothered somewhat by glare. 1% of Vivity patients and 2% of monofocal patients were bothered quite a bit by starbursts. 1% of Vivity patients and 1% of monofocal patients were bothered quite a bit by halos. 4% of Vivity patients and 3% of monofocal patients were bothered quite a bit by glare. 2% of Vivity patients and 1% of monofocal patients were bothered very much by starbursts. 1% of Vivity patients and 0% of monofocal patients were bothered very much by halos. 0% of Vivity patients and 0% of monofocal patients were bothered very much by glare.

*Results from a prospective, randomized, parallel group, subject and assessor masked, multisite trial of 107 subjects bilaterally implanted with AcrySof IQ Vivity® Extended Vision IOL and 113 with AcrySof® IQ IOL with 6 months follow-up. Visual disturbances were evaluated subjectively through QUVID questionnaire. Patients were asked: “In the past 7 days, how much were you bothered with starbursts, halos, and glare?”

†Vivity® IOL = AcrySof IQ Vivity®, Model DFT015

‡Monofocal IOL = AcrySof® IQ IOL, Model SN60WF

Vivity® is Designed to Provide a Superior Halo Profile Compared to Competitive EDOF Lenses16*†

A bar graph showing the percent of patients not bothered at all by halos three months after implantation. The blue bar signifying the Vivity IOL reaches 89%. The red bar signifying the TECNIS Symfony IOL reaches 58% and the light-grey bar signifying the Zeiss AT LARA IOL reaches 59%.

*Data come from a randomized (1:1:1), controlled, subject-and-assessor-masked, prospective trial. DFT015 was superior to Symfonyd (~31% difference; 97.5% CI 13.34, 46.79) and AT LARA‡ (~30% differences; 97.5% CI 12.54, 46.68).

†AcrySof IQ Vivity® was tested. AcrySof IQ Vivity® and Clareon® Vivity® are optically equivalent.

‡Trademarks are the property of their respective owners.

Vivity® is Designed to Have a Low Impact on Night Driving16

A bar graph showing the percent of patients not bothered at all by halos three months after implantation. The blue bar signifying the Vivity IOL reaches 89%. The red bar signifying the TECNIS Symfony IOL reaches 58% and the light-grey bar signifying the Zeiss AT LARA IOL reaches 59%.

*Data come from a randomized (1:1:1), controlled, subject-and-assessor-masked, prospective trial. DFT015 was superior to Symfony‡ (~31% difference; 97.5% CI 13.34, 46.79) and AT LARA‡ (~30% differences; 97.5% CI 12.54, 46.68). Patients were asked, “How much difficulty do you have driving at night because of your vision?”

†AcrySof IQ Vivity® was tested. AcrySof IQ Vivity® and Clareon® Vivity® are optically equivalent.

‡Trademarks are the property of their respective owners.

 
 
    Wavefront-Shaping Technology
    The Clareon® Vivity® IOL is a presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-2

     

    ✓ The Clareon® Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the Clareon® monofocal1,2

     

    ✓ Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2

     

    ✓ Surface Transition #2: A small curvature change (across the ~2.2 mm region) that shifts the wavefront to utilize all available light energy2

    Golden 3-dimensional image of the Clareon Vivity IOL.
    Surface Transition #1
    The Clareon® Vivity® IOL is a presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-2

     

    ✓ The Clareon® Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the Clareon® monofocal1,2

     

    ✓ Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2

     

    ✓ Surface Transition #2: A small curvature change (across the ~2.2 mm region) that shifts the wavefront to utilize all available light energy2

    Golden 3-dimensional image of the Clareon Vivity IOL with white graphic lines that draw focus to the middle of the lens, highlighting the slightly elevated smooth plateau that contributes to the lens’s wavefront-shaping technology.
    Surface Transition #2
    The Clareon® Vivity® IOL is a presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-2

     

    ✓ The Clareon® Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the Clareon® monofocal1,2

     

    ✓ Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2

     

    ✓ Surface Transition #2: A small curvature change (across the ~2.2 mm region) that shifts the wavefront to utilize all available light energy2

    Golden 3-dimensional image of the Clareon Vivity IOL with white graphic lines that draw focus to the middle of the lens highlighting the small curvature change that contributes to the lens’s wavefront-shaping technology.

    Unique Mechanism of Action

     

    The Clareon® Vivity® IOL uses wavefront shaping technology to deliver distance, intermediate, and functional near vision for patients, as well as a clinically proven exceptionally low rate of visual disturbances.1-4

     

    The wavefront-shaping technology of the Clareon® Vivity® IOL is called X-WAVE™ Technology and is proprietary to Alcon.

     

    Wavefront-shaping stretches the light. It doesn’t bend light like refraction, or split light like diffraction.

     

    Just like a monofocal, Clareon® Vivity® utilises essentially all of the transmitted light energy that passes through the lens. The smooth surface transition elements on the Clareon® Vivity® IOL stretch and shift the wavefront to provide a full range of vision with functional near visual acuity to help reduce spectacle dependence.1-4

    What is Clareon® Vivity®?

     

    Clareon® Vivity® wavefront-shaping technology explained.

    Surface Transition Elements Affect Light Energy Distribution*

     

    The proprietary, wavefront-shaping design creates a monofocal visual disturbance profile and a continuous range of vision for patients.1-4

    With the Clareon® Vivity® IOL, light spans a continuous focal range, instead of being split amongst multiple focal points.17

    A graphic illustrating the range of vision with four different IOLs. The AcrySof® IQ monofocal IOL provides distance vision. The Symfony IOL provides distance, intermediate and near vision. The AT LARA IOL provides vision at distance and two intermediate focal points. The AcrySof IQ Vivity® IOL provides a continuous range of vision from distance to functional near.

    *Simulated photopic through-focus point spread function (light intensity [energy]) – polychromatic.

    †Trademarks are the property of their respective owners.

      NIGHTTIME

      Clinically Proven Exceptionally Low Rate of Visual Disturbances1-4

      The picture displays the night-driving vision of someone with a monofocal IOL, with near objects out of focus.
      The image displays the night-driving vision of someone with a Clareon Vivity IOL, with near, intermediate and distance focal points in focus.
      Vision Simulation: Night-time Activity
      DAYTIME

      Clareon® Vivity® IOL Delivers Excellent Distance, Intermediate and Functional Near Vision3,4

      The picture displays this point of view from someone with a monofocal IOL. There are three grey circles with text. Each circle highlights the vision of someone with a monofocal IOL at near, intermediate and far distance, with near and intermediate focal points out of focus, and distance focal points in clear focus.
      The image displays this point of view from someone with a Clareon Vivity IOL. There are three blue circles with text. Each circle highlights the vision of someone with the Clareon Vivity IOL at near, intermediate and far distance, with all focal points in clear focus.
      Vision Simulation: Day-time Activity
      SMART Educator

      See Why Patients Say The Vivity® IOL Was The Right Choice For Them

      “In my case, [Vivity®] was the perfect choice… I’m extremely happy and extremely satisfied.” 

      - Roger, Spain

      Roger, Spain

       

      Roger is representative of patients whose active lifestyle makes them best suited for a lens that can offer them a continuous range of vision.

      Leslie, UK

       

      Leslie is like many patients who are most suited for a lens with a continuous range of vision in order to maintain their hobbies and active lifestyle.

      Dr. Angela Jennings, Australia

       

      Dr. Angela Jennings is an ophthalmologist and an AcrySof IQ Vivity® IOL patient who represents many patients who are considered unsuitable for PCIOLs; these include people with Type A personalities, people who drive at night, and who have mild glaucoma.

      Tracey, USA

       

      Tracey is like many patients whose active lifestyle makes them best suited for a lens that can offer them a continuous range of vision.

      The patients that appear in these videos express opinions that are their own, based on their own experiences. These videos are not a substitute for medical advice or information. The patients received a modest compensation for their participation in these videos.

      Clinical Support

      Bala C, et al. Multi-country clinical outcomes of a new nondiffractive presbyopia-correcting intraocular lens.

       

      Evaluating the effectiveness and safety of a novel presbyopia-correcting intraocular lens (IOL) with a nondiffractive design, DFT015, compared with an aspheric monofocal IOL, SN60WF.

      Guarro M, et al. Visual disturbances produced after the implantation of three EDOF intraocular lenses vs one monofocal intraocular lens.

       

      Comparing the visual disturbances experienced by patients receiving 1 of 3 extended depth-of-focus (EDOF) intraocular lenses (IOLs) or a monofocal IOL as the control.

      McCabe C, et al. Clinical outcomes in a U.S. registration study of a new EDOF intraocular lens with a nondiffractive design.

       

      Evaluating the effectiveness and safety of the DFT015 intraocular lens (IOL) (AcrySof IQ Vivity Extended Vision) compared with an aspheric monofocal control IOL (AcrySof IQ model SN60WF).

      Kohnen T, et al. The novel optical design and clinical classification of a wavefront-shaping presbyopia-correcting intraocular lens.

       

      Evaluating the clinical rationale of wavefront-shaping technology, describing how intraocular lenses (IOLs) using wavefront-shaping technology are differentiated from refractive or diffractive optical presbyopia-correcting designs, and describing the mode of action of this technology.

      Baur I, et al. Visualization of Ray Propagation through Extended Depth-of-Focus Intraocular Lenses

       

      Comparing the ray propagation and light intensity profiles of four IOLs: the non-diffractive AcrySof IQ Vivity, and two diffractive models, Symfony ZXR00 and AT Lara 829 MP. A fourth lens, the monofocal AcrySof IQ SN60WF acted as the control.

      Technical Specifications

      Table of specifications for Clareon Vivity

      *Clinically validated. †Theoretical.

      Instructions for Use (IFU)

       

      For a full list of indications, contraindications and warnings, please visit ifu.alcon.com and refer to the relevant product’s instructions for use.

      Visit IFU Database

      Alcon Experience Academy

       

      For relevant training content from industry thought leaders

      Visit AEA Portal

      References:

      1. Clareon® Vivity® Extended Vision IOL Directions for Use.

      2. Alcon Data on File. US Patent 9968440 B2. 15 May 2018.

      3. Bala C, et al. Multi-country clinical outcomes of a new nondiffractive presbyopia-correcting intraocular lens. J Cataract Refract Surg. 2021: Ahead of print. doi:10.1097/j.jcrs.0000000000000712.

      4. McCabe C, Berdahl J, Reiser H, et al. Clinical outcomes in a U.S. registration study of a new EDOF intraocular lens with a non-diffractive design. J Cataract Refract Surg. 2022;48(11):1297-1304.

      5. Baur I, et al. Visualization of ray propagation through extended depth-of-focus intraocular lenses. Diagnostics 2022, 12, 2667.

      6. Ligabue E, et al. ACRYSOF IQ VIVITY: Natural vision at a range of distances provided by a novel optical technology. Cataract & Refractive Surgery Today. April 2020.

      7. Lawless M. Insight news. “An IOL to change the cataract surgery paradigm?” available at “https://insightnews.com.au/an-iol-to-change-the-cataract-surgery-paradigm/”. Accessed 17 Jul 2020.

      8. Ahmed I, et al. The Vivity Extended Depth of Focus IOL: Our Clinical Experience. Cataract & Refractive Surgery Today. February 2021.

      9. Werner L, Thatthamla I, Ong M, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. J Cataract Refract Surg. 2019;45(10):1490-1497.

      10. Lane S, et al. Evaluation of intraocular lens mechanical stability. J Cataract Refract Surg. 2019;45:501-506.

      11. Walters T, et al. Rotational Stability of the Clareon Monofocal Aspheric Hydrophobic Acrylic Intraocular Lens 6 Months After Implantation. Clin Ophthalmol 2022;16:401.

      12. Von Tress M et al. A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials. Clin Ophthalmol 2018;12:1125.

      13. AcrySof® IQ Aspheric IOL Product Information.

      14. Clareon® Monofocal IOL Directions for Use.

      15. Alcon Data on File, REP-206331. 2021.

      16. Alcon Data on File, ILI875-P001. 2021.

      17. Kohnen T, et al. The Novel Optical Design and Clinical Classification of a Wavefront-Shaping Presbyopia-Correcting Intraocular Lens. Clin Ophthalmol. 2023:17 2449–2457.

       

      Please refer to product direction for use for complete list of indications, contraindications and warnings.

      ©2024 Alcon Inc. 02/24 GB-CLV-2400001
      International
      Alcon See Briliantly